Cullen Frost Bankers Inc. Purchases 444 Shares of CVS Health Corporation $CVS

Cullen Frost Bankers Inc. raised its position in shares of CVS Health Corporation (NYSE:CVS) by 7.7% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,190 shares of the pharmacy operator’s stock after acquiring an additional 444 shares during the period. Cullen Frost Bankers Inc.’s holdings in CVS Health were worth $427,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in CVS. GAMMA Investing LLC grew its holdings in shares of CVS Health by 198.5% in the first quarter. GAMMA Investing LLC now owns 18,669 shares of the pharmacy operator’s stock worth $1,265,000 after purchasing an additional 12,415 shares during the last quarter. Golden State Wealth Management LLC grew its holdings in shares of CVS Health by 5,096.1% in the first quarter. Golden State Wealth Management LLC now owns 3,949 shares of the pharmacy operator’s stock worth $268,000 after purchasing an additional 3,873 shares during the last quarter. Pure Financial Advisors LLC bought a new position in shares of CVS Health in the first quarter worth about $204,000. Sequoia Financial Advisors LLC grew its holdings in shares of CVS Health by 9.1% in the first quarter. Sequoia Financial Advisors LLC now owns 44,905 shares of the pharmacy operator’s stock worth $3,042,000 after purchasing an additional 3,748 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its holdings in shares of CVS Health by 33.8% in the first quarter. Robeco Institutional Asset Management B.V. now owns 290,990 shares of the pharmacy operator’s stock worth $19,715,000 after purchasing an additional 73,583 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on CVS. Leerink Partners upped their price target on shares of CVS Health from $86.00 to $95.00 and gave the stock an “outperform” rating in a report on Thursday, October 16th. Baird R W upgraded shares of CVS Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Robert W. Baird upgraded shares of CVS Health from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $71.00 to $82.00 in a report on Thursday, August 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $78.00 target price on shares of CVS Health in a report on Tuesday, August 26th. Finally, The Goldman Sachs Group started coverage on shares of CVS Health in a report on Tuesday, October 14th. They set a “buy” rating and a $91.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and an average price target of $83.38.

CVS Health Stock Performance

CVS stock opened at $81.95 on Friday. The firm has a market cap of $103.94 billion, a price-to-earnings ratio of 22.89, a PEG ratio of 0.89 and a beta of 0.60. The firm has a 50-day simple moving average of $75.57 and a two-hundred day simple moving average of $68.67. CVS Health Corporation has a one year low of $43.56 and a one year high of $83.52. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, beating the consensus estimate of $1.46 by $0.35. The business had revenue of $98.92 billion during the quarter, compared to analyst estimates of $94.87 billion. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The company’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.83 earnings per share. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts forecast that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health’s dividend payout ratio is presently 74.30%.

Insider Activity at CVS Health

In related news, Director Anne A. Finucane sold 7,500 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the transaction, the director directly owned 22,156 shares of the company’s stock, valued at $1,573,519.12. This trade represents a 25.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.22% of the company’s stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.